Literature DB >> 20706038

Tc-99m MIBI scintigraphy in multiple myeloma: prognostic value of different Tc-99m MIBI uptake patterns.

Jaroslav Bacovsky1, Miroslav Myslivecek, Vlastimil Scudla, Pavel Koranda, Eva Buriankova, Jiri Minarik, Tomas Pika, Jana Zapletalova.   

Abstract

PURPOSE: Technetium-99m 2 methoxyisobutylisonitrile (Tc-99m MIBI) scintigraphy has been used to identify biologic activity and extent of multiple myeloma (MM) and monoclonal gammopathy of unknown significance (MGUS). The examination could also serve both as a prognostic tool and an examination for monitoring the disease course in MM patients. The purpose of this study was to evaluate the prognostic value of different Tc-99m MIBI uptake patterns.
MATERIALS AND METHODS: Ninety-nine consecutive patients with newly diagnosed symptomatic MM and 18 patients with MGUS underwent baseline Tc-99m MIBI scintigraphy before applying any kind of therapy. The Tc-99m MIBI scans were classified as showing normal, diffuse, and focal or combined (diffuse and focal) patterns of tracer uptake. To evaluate the prognostic value of different Tc-99m MIBI uptake patterns, overall survival (OS) was chosen as an end point. Median of follow-up period was 84 months. Survival according to patterns of Tc-99m MIBI uptake was calculated using the Kaplan-Meier plots.
RESULTS: Statistically significant correlation between the baseline patterns of Tc-99m MIBI uptake and OS was found (P < 0.0001). Focal or combined patterns of Tc-99m MIBI uptake indicated significantly worse prognosis with shorter OS than normal or diffuse tracer patterns.
CONCLUSIONS: Tc-99m MIBI scintigraphy plays the predictive role in the follow-up of patients with MM. Baseline scintigraphic pattern of Tc-99m MIBI uptake seems to be a useful prognostic indicator of OS in MM patients and Tc-99m MIBI scintigraphy could be used as an additional tool for the initial examination in patients with newly diagnosed MM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20706038     DOI: 10.1097/RLU.0b013e3181e9f92e

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  2 in total

1.  Marked gastric uptake of Tc-99m methylene diphosphonate (MDP) in a patient with myeloma and hypercalcemia.

Authors:  Kieran Foley; Patrick Fielding Mrcp
Journal:  Radiol Case Rep       Date:  2015-12-07

2.  99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma.

Authors:  Camila Mosci; Fernando V Pericole; Gislaine B Oliveira; Marcia T Delamain; Maria E S Takahashi; José Barreto C Carvalheira; Elba C S C Etchebehere; Allan O Santos; Eliana C M Miranda; Mariana C L Lima; Barbara J Amorim; Carmino A de Souza; Irene Lorand-Metze; Celso D Ramos
Journal:  Nucl Med Commun       Date:  2020-10       Impact factor: 1.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.